Lindsey Gasparini

At NeoGenomics Laboratories, my leadership in sales, commercial strategy, and data products is driven by a dedication to precision medicine and a command of real-world data. The role capitalizes on my strategic acumen in forging robust pharma partnerships, fostering market readiness, and enhancing physician training. My approach is proactive and data-driven, ensuring that every commercial initiative supports our mission to advance cancer diagnostics and treatment. In the last 3 years, I completed certificates at Harvard Business School in Disruptive Strategy, AI Business Essentials and corporate finance which has equipped me with skills and frameworks to identify and pursue innovative solutions and business models in the rapidly evolving healthcare industry. I have also contributed to various initiatives such as new product development, positioning and sales excellence. My specialties include molecular diagnostics, NGS (next-generation sequencing), liquid biopsy testing, minimal residual disease (MRD), IHC, flow cytometry, FISH, cytogenetics, product marketing, and sales process. I am passionate about leveraging oncology data and insights to improve patient outcomes, accelerate drug development, and enhance clinical decision making in oncology.